A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

NCT01897480 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: LY2875358
DRUG: Erlotinib

Sponsor

Eli Lilly and Company